SCHEMBL17034776

SCHEMBL17034776

CC(C)NC(=O)NCc1nn[nH]n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 3/20 0.48
NAALAD2 Q9Y3Q0 3/20 0.47
KDM6B O15054 1/20 0.42
KDM4A O75164 1/20 0.42
KDM5A P29375 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HPGDS O60760 1/20 0.39
EPHX2 P34913 2/20 0.39
PLA2G2C Q5R387 2/20 0.39
EPHX1 P07099 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.36
PADI4 Q9UM07 1/20 0.36
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17037043 0.81 KDM6B (0.46) FPR2NAALAD2KDM6BKDM4AKDM5A
SCHEMBL19755641 0.80 FPR2 (0.50) FPR2NAALAD2KDM6BKDM4AKDM5A
SCHEMBL25097470 0.80 CA12 (0.46) FPR2NAALAD2KDM6BKDM4AKDM5A
SCHEMBL12445440 0.78 KDM6B (0.49) FPR2NAALAD2KDM6BKDM4AKDM5A
SCHEMBL25097162 0.76 CA12 (0.43) FPR2NAALAD2KDM6BKDM4AKDM5A
SCHEMBL18116301 0.76 KDM6B (0.51) FPR2NAALAD2KDM6BKDM4AKDM5A
SCHEMBL22567137 0.76 NAALAD2 (0.43) FPR2NAALAD2KDM6BKDM4AKDM5A
SCHEMBL3051612 0.75 KDM6B (0.50) FPR2NAALAD2KDM6BKDM4AKDM5A
SCHEMBL13690454 0.75 FPR2 (0.47) FPR2NAALAD2KDM6BKDM4AKDM5A
SCHEMBL17038777 0.75 CA12 (0.47) FPR2NAALAD2KDM6BKDM4AKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005802-B2 Amide compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2018-06-26 US disclosed
US-10005802-B2 Amide compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2018-06-26 US disclosed
US-20170298084-A1 AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-10-19 US disclosed
US-9695205-B2 Amide compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-07-04 US disclosed
US-20160362398-A1 AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2016-12-15 US disclosed
US-20150239893-A1 Amide Compounds for Treatment of Complement Mediated Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362398-A1 AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS CFD, TFPI, CFH FPR2 203/4885NAALAD2 195/4885KDM6B 4658/4885
US-20170298084-A1 AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS CFD, TFPI, C9 FPR2 164/4885NAALAD2 206/4885KDM6B 4758/4885
US-10005802-B2 Amide compounds for treatment of complement mediated disorders CFD, TFPI, CFH FPR2 203/4885NAALAD2 195/4885KDM6B 4658/4885
US-20150239893-A1 Amide Compounds for Treatment of Complement Mediated Disorders CFD, TFPI, C9 FPR2 164/4885NAALAD2 206/4885KDM6B 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.